Scynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral RatingSeeking Alpha • 05/19/23
WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant PathogensNewsfile Corp • 05/19/23
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)GlobeNewsWire • 05/12/23
SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in DenmarkGlobeNewsWire • 04/13/23
SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/31/23
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal InfectionGlobeNewsWire • 03/30/23
SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant FungiGlobeNewsWire • 11/30/22
SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal ThreatsGlobeNewsWire • 11/17/22
SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/22
SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of FungiGlobeNewsWire • 11/07/22
Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to DeclineZacks Investment Research • 11/02/22
SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9GlobeNewsWire • 11/01/22
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022GlobeNewsWire • 10/24/22
SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class AntifungalGlobeNewsWire • 10/20/22
SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022GlobeNewsWire • 10/11/22